In conclusion, as far as we know, this is the first systematic study to elucidate the role of IGF2BP3 in pan-cancer from various angles, including its expression pattern, diagnosis, survival prognosis, genetic mutation, TMB, MSI, tumor immune microenvironment, relevant signaling pathways, and drug sensitivity. The gene discussed is IGF2BP3; the disease is cancer.